Serum microRNAs dysregulation in cervical cancer and their diagnostic role: A systematic review

Hussein Hameed Abbas; Fenwick Antony Edwin Rodrigues; Sivasamy Ramasamy

doi:10.51248/.v43i5.3181

Authors

Hussein Hameed Abbas
Fenwick Antony Edwin Rodrigues
Sivasamy Ramasamy https://orcid.org/0000-0001-6411-5876

DOI:

https://doi.org/10.51248/.v43i5.3181

Keywords:

Cervical cancer, miRNA, dysregulation, diagnosis

Abstract

Cervical cancer is the fourth-highest prevalent tumor among women in the world. Though the development in the early diagnosis of cervical cancer in developed countries, developing countries are still suffering from it. Among the different biomarkers, serum microRNAs (miRNAs) were reported as valuable tools in the diagnosis of cervical cancer. To highlight the most recent studies of the serum miRNAs in cervical cancer diagnosis, we systematically searched science direct and Web of Science databases using keywords, and the articles that meet inclusion criteria and do not meet exclusion criteria are included in the current review for further analysis. After applying the current study inclusion and exclusion criteria we found 42 dysregulated miRNAs, among them miR-21 was the most investigated, and most of them were capable of distinguishing between healthy and cervical cancer subjects. The current study shows the importance of serum miRNAs as biomarkers in cervical cancer diagnosis.

Author Biographies

Hussein Hameed Abbas

Department of Human Genetics and Molecular Biology, Bharathiar University, Maruthamalai Main Road, Coimbatore, 641046, Tamil Nadu, India

Fenwick Antony Edwin Rodrigues

Department of Human Genetics and Molecular Biology, Bharathiar University, Maruthamalai Main Road, Coimbatore, 641046, Tamil Nadu, India

Sivasamy Ramasamy

Department of Human Genetics and Molecular Biology, Bharathiar University, Maruthamalai Main Road, Coimbatore, 641046, Tamil Nadu, India

References

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: CA Cancer J Clin. 2021;71(3): 209-249.

Sowkanthika, P., Maitreyee, D.S., D’Almeida, J., Shivashankara, A.R., Avinash, S.S., Premakumari, E., et al., Correlation of serum gamma-glutamyl transferase and serum glutathione-S-transferase with PAP smear as screening tests for cervical cancer. Biomedicine. 2023 Jul 1;43(3):855-858.

Sharshenbaeva, A., Lim, E., Zhumabekova, A., Musaev, U., Vaninov, A., Kudaibergenova, I., et al., The role of neoadjuvant polychemotherapy in the treatment of patients with stage IIB cervical cancer. Biomedicine. 2023 Feb 26;43(1):201-204.

Waggoner, S. E. Cervical cancer.The Lancet.2003;361(9376): 2217-2225.

Haque, A., Kouriba, B., Aissatou, N. d., Pant, A. Eliminating cervical cancer in Mali and Senegal, two sub-saharan countries: Insights and optimizing solutions. Vaccines. 2020; 8(2): 181.

Tsikouras, P., Zervoudis, S., Manav, B., Tomara, E., Iatrakis, G., Romanidis, C., et al., Cervical cancer: Screening, diagnosis and staging. J Buon. 2016; 21(2): 320-325.

Keeratichamroen, S., Subhasitanont, P., Chokchaichamnankit, D., Weeraphan, C., Saharat, K., Sritana, N., et al., Identification of potential cervical cancer serum biomarkers in Thai patients. Oncol Lett. 2020; 19(6): 3815-3826.

O'Brien, J., Hayder, H., Zayed, Y., Peng, C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018; 9: 402.

Filipow, S., Laczmanski, L. Blood circulating miRNAs as cancer biomarkers for diagnosis and surgical treatment response. Front Genet. 2019;10: 169.

Schwarzenbach, H., Nishida, N., Calin, G. A., Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-156.

Li, D., Ge, X., Liu, P. Changes of MIR-144-3P and MIR-337-3P in serum of cervical carcinoma patients and analysis of diagnosis and prognosis. Acta Medica Mediterr. 2021; 37(5): 2809-2815.

Yang, D., Zhang, Q. miR-152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer. Oncol Lett. 2019; 17(6): 5693-5698.

Qiu, H., Liang, D., Liu, L., Xiang, Q., Yi, Z., Ji, Y. A novel circulating miRNA-based signature for the diagnosis and prognosis prediction of early-stage cervical cancer. Technol Cancer Res Treat. 2020; 19: 1533033820970667.

Zhu, D., Hao, Q., Qian, M., Hu, Y., Wu, F. LncRNA ABHD11-AS1 participates in the progression of cervical carcinoma by targeting miR-1254 and is the key to the diagnosis and treatment of cervical carcinoma in the future. J Healthc Eng. 2022; 2022. http://doi.org/10.1155/2022/ 8387458

Aftab, M., Poojary, S. S., Seshan, V., Kumar, S., Agarwal, P., Tandon, S., et al., Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer. Sci Rep. 2021;11(1): 0323.

Wang, P., Zhai, G., Bai, Y. Values of miR-34a and miR-218 expression in the diagnosis of cervical cancer and the prediction of prognosis. Oncol Lett. 2018; 15(3): 3580-3585.

Zhang, L., Wu, Z. A. MicroRNA-378a-3p downregulation as a novel biomarker with poor clinical outcomes in cervical cancer. Biomed Environ Sci. 2021;34(3):213-221.

Cao, S., Li, H., Li, L. LncRNA SNHG17 contributes to the progression of cervical cancer by targeting microRNA-375-3p. Cancer Manag Res. 2021:4969-4978.

Dai, Y., Xie, F., Chen, Y. Retracted: Reduced levels of miR-485-5p in HPV-infected cervical cancer promote cell proliferation and enhance invasion ability. FEBS Open Bio. 2020;10(7):1348-1361.

Ruan, F., Wang, Y.f., Chai, Y. Diagnostic values of miR-21, miR-124, and M-CSF in patients with early cervical cancer. Technol Cancer Res Treat. 2020; 19: 1533033820914983.

Zheng, S., Li, R., Liang, J., Wen, Z., Huang, X., Du, X., et al., Serum miR-638 combined with squamous cell carcinoma-related antigen as potential screening biomarkers for cervical squamous cell carcinoma. Genet Test Mol Biomarkers. 2020; 24(4):188-194.

Sun, J., Wang, S., Liu, P., Liu, Y. MiR-139-5p-ZEB1 is a molecular regulator of growth, invasion, and epithelial-to-mesenchymal transition of cervical cancer. Cancer Manag Res.2020:10(12):12723-12733.

Li, Z., Lin, Y. LncRNA TUG1 accelerates cervical cancer progression through miR-29b. Int J Clin Exp Med. 2020; 13(11):8326-8339.

Shukla, V., Varghese, V. K., Kabekkodu, S. P., Mallya, S., Chakrabarty, S., Jayaram, P., et al., Enumeration of deregulated miRNAs in liquid and tissue biopsies of cervical cancer. Gynecol Oncol. 2019;155(1):135-143.

Yamanaka, Z., Sasaki, T., Yamanaka, A., Kato, K., Nishi, H. Circulating and tissue miR100 acts as a potential diagnostic biomarker for cervical cancer. Cancer Biomarkers.2021;32 (4): 551-558.

Wang, J., Zhu, Z., Qiu, H., Liu, C., Chang, X., Qi, Y., et al., LncRNA NKILA inhibits the proliferation and promotes the apoptosis of CSCC cells by downregulating miRNA21. J Cell Physiol.2020; 235(11): 7863-7869.

Zhang, W., Zhang, J., Zhang, Q., Hu, F., Gu, Y. Highly specific real-time quantification of diverse microRNAs in human samples using universal primer set frame. Anal Biochem. 2018; 543:71-78.

Zhang, Z., Wang, J., Wang, X., Song, W., Shi, Y., Zhang, L. MicroRNA-21 promotes proliferation, migration, and invasion of cervical cancer through targeting TIMP3. Arch Gynecol Obstet. 2018; 297: 433-442.

Zhou, C., Wei, W., Ma, J., Yang, Y., Liang, L., Zhang, Y., et al., Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels. Mol Ther. 2021;29(4):1512-1528.

Lu, H., Gu, X. MicroRNA-221 inhibits human papillomavirus 16 E1-E2 mediated DNA replication through activating SOCS1/Type I IFN signaling pathway. Int J Clin Exp Pathol. 2019;12(5):1518.

Wang, Z., Wang, W., Zhao, W., Wang, Z., Yang, J., Wang, W., et al., Folate inhibits miR-27a-3p expression during cervical carcinoma progression and oncogenic activity in human cervical cancer cells. Biomed Pharmacother. 2020; 122: 109654.

Du, S., Zhao, Y., Lv, C., Wei, M., Gao, Z., Meng, X. Applying serum proteins and microRNA as novel biomarkers for early-stage cervical cancer detection. Sci Rep. 2020;10(1): 9033.

Li, C., Zheng, X., Li, W., Bai, F., Lyu, J., Meng, Q. H. Serum miR-486-5p as a diagnostic marker in cervical cancer: with investigation of potential mechanisms. BMC Cancer. 2018; 18(1):1-10.

Luo, Q., Wang, H., Li, J. Serum miR-3142 could be used as a potential biomarker to screen cervical cancer patients from healthy controls. Clin Lab. 2019;65(4):doi:10.7754/Clin. Lab.2018.180925.

Ocadiz Delgado, R., Lizcano Meneses, S., Trejo-Vazquez, J. A., Conde Perezprina, J. C., Garrido Palmas, F., Alvarez Rios, E., et al., Circulating miR 15b, miR 34a and miR 218 as promising novel early low invasive biomarkers of cervical carcinogenesis. Apmis. 2021; 129(2): 70-79.

Zhang, Y., Qiu, S., Guo, Y., Zhang, J., Wu, X., Hong, G. Diagnostic value of vaginal microecology, serum miR18a, and PDL1 for identifying HPVpositive cervical cancer. Technol Cancer Res Treat. 2021; 20: 1533033821995281.

Cai, Y., Zhang, K., Cao, L., Sun, H., Wang, H. Inhibition of microrna-766-5p attenuates the development of cervical cancer through regulating SCAI. Technol Cancer Res Treat. 2020; 19:1533033820980081.

Farzanehpour, M., Mozhgani, S.-H., Jalilvand, S., Faghihloo, E., Akhavan, S., Salimi, V., et al., Serum and tissue miRNAs: potential biomarkers for the diagnosis of cervical cancer. Virol J. 2019; 16: 1-9.

Yang, Z., Sun, Q., Guo, J., Wang, S., Song, G., Liu, W., et al., GRSF1-mediated MIR-G-1 promotes malignant behavior and nuclear autophagy by directly upregulating TMED5 and LMNB1 in cervical cancer cells. Autophagy. 2019; 15(4): 668-685.

Wang, J., Liu, Y., Wang, X., Li, J., Wei, J., Wang, Y., et al., MiR-1266 promotes cell proliferation, migration and invasion in cervical cancer by targeting DAB2IP. Biochim Biophys Acta (BBA)-Molecular Basis Dis. 2018; 1864(12): 3623-3630.

Zhang, Z., Wang, J., Li, J., Wang, X., Song, W. MicroRNA-150 promotes cell proliferation, migration, and invasion of cervical cancer through targeting PDCD4. Biomed Pharmacother. 2018; 97: 511-517.